BEZ235

DRUG16 trials

Sponsors

Novartis Pharmaceuticals, Vanderbilt-Ingram Cancer Center, SCRI Development Innovations, LLC, Memorial Sloan Kettering Cancer Center, University of Cincinnati

Conditions

Acute Lymphoblastic LeukemiaAdvanced Solid TumorAdvanced Solid TumorsBreast CancerCancerCarcinoma Transitional CellCastrate-resistant Prostate CancerCastration-resistant Prostate Cancer

Phase 1

A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer

CompletedNCT00620594

Novartis PharmaceuticalsAdvanced Solid Tumors, Breast Cancer, Cowden Syndrome

Start: 2006-12-21End: 2013-01-08Updated: 2020-12-09

A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors

CompletedNCT01195376

Novartis PharmaceuticalsAdvanced Solid Tumor

Start: 2010-10-31End: 2013-07-31Updated: 2020-12-09

PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer

CompletedNCT01248494

Vanderbilt-Ingram Cancer CenterMetastatic Breast Cancer

Start: 2010-11-30End: 2016-05-31Updated: 2016-07-25

Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors

CompletedNCT01343498

SCRI Development Innovations, LLCMalignant Solid Tumour

Start: 2011-04-30End: 2014-01-31Updated: 2015-05-01

BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)

TerminatedNCT01453595

Memorial Sloan Kettering Cancer CenterRenal Cancer

Start: 2011-10-31End: 2014-04-30Updated: 2016-02-29

Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer

TerminatedNCT01495247

Novartis PharmaceuticalsInoperable Locally Advanced Breast Cancer, Metastatic Breast Cancer (MBC)

Start: 2012-01-30End: 2014-05-19Updated: 2020-12-08

Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors

TerminatedNCT01508104

University of CincinnatiCancer

Start: 2012-01-31End: 2014-12-31Updated: 2017-08-23

Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients

CompletedNCT01634061

Novartis PharmaceuticalsCastration-resistant Prostate Cancer

Start: 2012-09-30End: 2015-07-31Updated: 2020-12-09

A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer

TerminatedNCT01717898

Charles RyanCastrate-resistant Prostate Cancer

Start: 2013-01-31End: 2016-08-29Updated: 2018-03-27

A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia

CompletedNCT01756118

Goethe UniversityAcute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia With Crisis of Blast Cells, Leukemia, Myelocytic, Acute

Start: 2012-06-30End: 2020-02-07Updated: 2023-02-16

Phase 2

BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer

WithdrawnNCT01288092

Novartis PharmaceuticalsMetastatic Breast Cancer

Start: 2012-03-31Updated: 2012-06-07

BEZ235 Trial in Patients With Advanced Endometrial Carcinoma

WithdrawnNCT01290406

Novartis PharmaceuticalsEndometrial Cancer

Start: 2012-03-31End: 2017-12-31Updated: 2012-06-21

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

TerminatedNCT01628913

Novartis PharmaceuticalsPancreatic Neuroendocrine Tumors (pNET)

Start: 2012-10-31End: 2014-09-30Updated: 2016-04-07

A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa

WithdrawnNCT01690871

Novartis PharmaceuticalsMalignant PEComa (Perivascular Epithelioid Cell Tumors)

Start: 2012-09-30End: 2015-01-31Updated: 2013-08-02

Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based Chemotherapy

TerminatedNCT01856101

Cliniques universitaires Saint-Luc- Université Catholique de LouvainCarcinoma Transitional Cell

Start: 2013-02-28End: 2014-01-31Updated: 2019-04-10

Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly

Active, not recruitingNCT03373903

Restorbio Inc.Respiratory Tract Infections

Start: 2017-11-15End: 2018-07-31Updated: 2018-05-16

Related Papers

Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials.

2021-05-0678 citations

A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia.

2020-09-2926 citations

A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors.

2018-11-1610 citations

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies.

2017-06-0193 citations

Phase II studies of BEZ235 in patients with advanced pancreatic neuroendocrine tumors (pNET).

Journal of Clinical Oncology2015-05-2013 citations

Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma (TCC).

Journal of Clinical Oncology2015-05-204 citations

Results of a multicenter phase I/II trial of abiraterone acetate plus BEZ235 in metastatic, castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2014-05-206 citations

Abstract P2-16-22: A dose-finding phase lb study of BEZ235 in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer

Cancer Research2013-12-154 citations

Abstract A167: A phase I study of single-agent BEZ235 (SDS sachet), once- or twice-daily, in Japanese patients with advanced solid tumors.

Molecular Cancer Therapeutics2013-11-01